Identification of Tripeptide Inhibitors Targeting MAPK3 in Leishmania martiniquensis and Leishmania orientalis Using Molecular Modeling, Virtual Screening, Molecular Dynamics, and In Vitro Approach

利用分子建模、虚拟筛选、分子动力学和体外实验方法鉴定马提尼克利什曼原虫和东方利什曼原虫中靶向 MAPK3 的三肽抑制剂

阅读:2

Abstract

MAPK3 has been identified as a potential drug target due to its role in the Leishmania life cycle. This study focused on two species prevalent in Thailand: Leishmania martiniquensis and Leishmania orientalis. Using an in silico strategies, we screened an in-house library of 8000 tripeptides to identify potential MAPK3 inhibitors. A multi-level computational workflow was employed, including homology modeling, molecular docking study, and molecular dynamics (MD) simulations. Promising candidates were further validated by an in vitro kinase assay. The three-dimensional (3D) structures of MAPK3 from L.martiniquensis and L. orientalis were constructed by using the Swiss Model. Structure-based virtual screening identified nine promising tripeptides, with WSY demonstrated strong binding affinity, MD simulation and MM-GBSA binding free energy calculation confirmed its stable interaction with key regions in the MAPK3 active site, including the DFG motif, hinge region, αC-helix through hydrogen bonds, hydrophobic interaction, and π-π stacking. In vitro kinase assays demonstrated that the peptide WSY was significantly more effective at inhibiting MAPK3 than WHW, with IC(50) values of 0.9 ± 11.3 and 26.9 ± 6.7 μM, respectively. These findings suggest that WSY is a promising anti-leishmanial drug candidate targeting LmqMAPK3 and LoMAPK3. Our hybrid computational-experimental approach provides a solid framework for identification of novel inhibitors and can be extended to other compound libraries to help the discovery of new anti-leishmania therapies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。